Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Mouse and human striatal projection neurons compared - somatodendritic arbor, spines and in silico analyses

  • Kozlov, Alexander
  • Blazquez Llorca, Lidia
  • Benavides Piccione, Ruth
  • Kastanauskaite, Asta
  • Rojo, Ana I.
  • Muñoz Céspedes, Alberto
  • Cuadrado, Antonio
  • DeFelipe, Javier
  • Grillner, Sten
Dysfunction of the basal ganglia is implicated in a wide range of neurological and psychiatric disorders. Our understanding of the operation of the basal ganglia is largely derived on data from studies conducted on mice, which are frequently used as model organisms for various clinical conditions. The striatum, the largest compartment of the basal ganglia, consists of 90-95% striatal projection neurons (SPNs). It is therefore crucial to establish if human and mouse SPNs have distinct or similar properties, as this has implications for the relevance of mouse models for understanding the human striatum. To address this, we compared the general organization of the somato-dendritic tree of SPNs, the dimensions of the dendrites, the density and size of spines (spine surface area), and ion channel subtypes in human and mouse SPNs. Our findings reveal that human SPNs are significantly larger, but otherwise the organisation of the dendritic tree (dendrogram) with an average of approximately 5 primary dendrites, is similar in both species. Additionally in both humans and mice, over 90% of the spines are located on the terminal branches of each dendrite. Human spines are somewhat larger (4.3 versus 3.1 μm2) and the terminal dendrites have a uniform diameter in both humans and mice, although somewhat broader in the latter (1.0 versus 0.6 μm). The composition of ion channels is also largely conserved. These data have been used to simulate human SPNs building on our previous detailed simulation of mouse SPNs. We conclude that the human SPNs essentially appear as enlarged versions of the mouse SPNs. This similarity suggests that both species process information in a comparable manner, supporting the relevance of mouse models for studying the human striatum.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overlooked and valuable facts to know in the NRF2/KEAP1 field

  • Kopacz, Aleksandra
  • Rojo, Ana I.
  • Patibandla, Chinmai
  • Lastra, Diego
  • Piechota-Polanczyk, Aleksandra
  • Kloska, Damian
  • Jozkowicz, Alicja
  • Sutherland, Calum
  • Cuadrado, Antonio
  • Grochot-Przeczek, Anna
NRF2 (nuclear factor erythroid 2-related factor 2) is a critical regulator of the cellular stress response. It is a transcription factor that controls the expression of hundreds of genes. We will soon celebrate the thirtieth anniversary of its discovery [1]. Over the years, NRF2 and its repressor KEAP1 have become the subject of intensive research, ranging from the detailed molecular mechanisms of their activity to clinical perspectives and generating over a dozen thousand publications. This review intends to draw the attention of researchers to essential issues in the NRF2/KEAP1 field, highlighting the overlooked facts and clarifying potential misconceptions., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, and PDC2021-121421-I00) and The Autonomous Community of Madrid (grant B2017/BMD-3827). FLM enjoyed FPI contract of MINECO (FPI-2017). The National Science Centre supported this work with grants Sonata Bis No. 2016/22/E/NZ3/00405 (AGP), Opus No. 2021/43/B/NZ4/02130 (AGP), and Sonata No. 2018/31/D/NZ4/00077 (APP). AK is supported by L'Oreal for Women in Science and START Scholarship from Foundation for Polish Science. CP and CS are supported by Diabetes UK award 20/0006178.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Escoll, Maribel
  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • García-Yagüe, Ángel Juan
  • González-Rodríguez, Águeda
  • García-Martínez, Irma
  • Valverde, Ángela M.
  • Rojo, Ana I.
  • Cuadrado, Antonio
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that compromises liver function, for which there is not a specifically approved medicine. Recent research has identified transcription factor NRF2 as a potential therapeutic target. However, current NRF2 activators, designed to inhibit its repressor KEAP1, exhibit unwanted side effects. Alternatively, we previously introduced PHAR, a protein-protein interaction inhibitor of NRF2/β-TrCP, which induces a mild NRF2 activation and selectively activates NRF2 in the liver, close to normal physiological levels. Herein, we assessed the effect of PHAR in protection against NASH and its progression to fibrosis. We conducted experiments to demonstrate that PHAR effectively activated NRF2 in hepatocytes, Kupffer cells, and stellate cells. Then, we used the STAM mouse model of NASH, based on partial damage of endocrine pancreas and insulin secretion impairment, followed by a high fat diet. Non-invasive analysis using MRI revealed that PHAR protects against liver fat accumulation. Moreover, PHAR attenuated key markers of NASH progression, including liver steatosis, hepatocellular ballooning, inflammation, and fibrosis. Notably, transcriptomic data indicate that PHAR led to upregulation of 3 anti-fibrotic genes (Plg, Serpina1a, and Bmp7) and downregulation of 6 pro-fibrotic (including Acta2 and Col3a1), 11 extracellular matrix remodeling, and 8 inflammatory genes. Overall, our study suggests that the mild activation of NRF2 via the protein-protein interaction inhibitor PHAR holds promise as a strategy for addressing NASH and its progression to liver fibrosis., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00, MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union.), CIBERdem and CIBERned (ISCIII), and The Autonomous Community of Madrid (grant P2022/BMD-7230). RFG enjoyed a FPI contract of MINECO (FPI-2017). DCS is a holder of a FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier

  • Cazalla, Eduardo
  • Cuadrado, Antonio
  • García-Yagüe, Ángel Juan
[Background]: The Blood-Brain Barrier (BBB) is a complex and dynamic interface that regulates the exchange of molecules and cells between the blood and the central nervous system. It undergoes structural and functional throughout oxidative stress and inflammation, which may compromise its integrity and contribute to the pathogenesis of neurodegenerative diseases., [Main body]: Maintaining BBB integrity is of utmost importance in preventing a wide range of neurological disorders. NRF2 is the main transcription factor that regulates cellular redox balance and inflammation-related gene expression. It has also demonstrated a potential role in regulating tight junction integrity and contributing to the inhibition of ECM remodeling, by reducing the expression of several metalloprotease family members involved in maintaining BBB function. Overall, we review current insights on the role of NRF2 in addressing protection against the effects of BBB dysfunction, discuss its involvement in BBB maintenance in different neuropathological diseases, as well as, some of its potential activators that have been used in vitro and in vivo animal models for preventing barrier dysfunction., [Conclusions]: Thus, emerging evidence suggests that upregulation of NRF2 and its target genes could suppress oxidative stress, and neuroinflammation, restore BBB integrity, and increase its protection., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grands PDC2021-121421-I00, PDC2022-1337665-I00, PID2022-141786OB-I00 and PID2019-110061RB-I00). The Autonomous Community of Madrid (grands S2017BMD-3827 and P2022_BMD-7230). EC is holder of an FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of glycogen synthase kinase-3 enhances NRF2 protein stability, nuclear localisation and target gene transcription in pancreatic beta cells

  • Patibandla, Chinmai
  • Aalten, Lidy van
  • Dinkova-Kostova, A. T.
  • Honda, Tadashi
  • Cuadrado, Antonio
  • Fernández-Ginés, Raquel
  • McNeilly, Alison D.
  • Hayes, John D.
  • Cantley, James
  • Sutherland, Calum
Accumulation of reactive oxygen species (i.e., oxidative stress) is a leading cause of beta cell dysfunction and apoptosis in diabetes. NRF2 (NF-E2 p45-related factor-2) regulates the adaptation to oxidative stress, and its activity is negatively regulated by the redox-sensitive CUL3 (cullin-3) ubiquitin ligase substrate adaptor KEAP1 (Kelch-like ECH-associated protein-1). Additionally, NRF2 is repressed by the insulin-regulated Glycogen Synthase Kinase-3 (GSK3). We have demonstrated that phosphorylation of NRF2 by GSK3 enhances β-TrCP (beta-transducin repeat-containing protein) binding and ubiquitylation by CUL1 (cullin-1), resulting in increased proteasomal degradation of NRF2. Thus, we hypothesise that inhibition of GSK3 activity or β-TrCP binding upregulates NRF2 and so protects beta cells against oxidative stress. We have found that treating the pancreatic beta cell line INS-1 832/13 with the KEAP1 inhibitor TBE31 significantly enhanced NRF2 protein levels. The presence of the GSK3 inhibitor CT99021 or the β-TrCP-NRF2 protein-protein interaction inhibitor PHAR, along with TBE31, resulted in prolonged NRF2 stability and enhanced nuclear localisation (P < 0.05). TBE31-mediated induction of NRF2-target genes encoding NAD(P)H quinone oxidoreductase 1 (Nqo1), glutamate-cysteine ligase modifier (Gclm) subunit and heme oxygenase (Hmox1) was significantly enhanced by the presence of CT99021 or PHAR (P < 0.05) in both INS-1 832/13 and in isolated mouse islets. Identical results were obtained using structurally distinct GSK3 inhibitors and inhibition of KEAP1 with sulforaphane. In summary, we demonstrate that GSK3 and β-TrCP/CUL1 regulate the proteasomal degradation of NRF2, enhancing the impact of KEAP1 regulation, and so contributes to the redox status of pancreatic beta cells. Inhibition of GSK3, or β-TrCP/CUL1 binding to NRF2 may represent a strategy to protect beta cells from oxidative stress., This work was supported by a Diabetes UK research grant [grant ref:20/0006178] awarded to CS, JC, JDH and AMN; MICINN grants PDC2021-121421-I00, PDC2022-133765-I00 and PID2022-141786OB-I00 awarded to AC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases

  • Rojo, Ana I.
  • Buttari, Brigitta
  • Cadenas, Susana
  • Carlos, Ana Rita
  • Cuadrado, Antonio
  • Falcão, Ana Sofia
  • López, Manuela G.
  • Georgiev, Milen I.
  • Grochot-Przeczek, Anna
  • Gumeni, Sentiljana
  • Jiménez-Villegas, José
  • Horbanczuk, Jarosław Olav
  • Konu, Ozlen
  • Lastres Becker, Isabel
  • Levonen, Anna-Liisa
  • Maksimova, Viktorija
  • Michaeloudes, Charalambos
  • Mihaylova, Liliya V
  • Mickael, Michel Edwar
  • Milisav, Irina
  • Miova, Biljana
  • Rada, Patricia
  • Santos, Marlene
  • Seabra, Miguel C
  • Strac, Dubravka Svob
  • Tenreiro, Sandra
  • Trougakos, Ioannis P
  • Dinkova-Kostova, Albena T
Non-communicable chronic diseases (NCDs) are most commonly characterized by age-related loss of homeostasis and/or by cumulative exposures to environmental factors, which lead to low-grade sustained generation of reactive oxygen species (ROS), chronic inflammation and metabolic imbalance. Nuclear factor erythroid 2-like 2 (NRF2) is a basic leucine-zipper transcription factor that regulates the cellular redox homeostasis. NRF2 controls the expression of more than 250 human genes that share in their regulatory regions a cis-acting enhancer termed the antioxidant response element (ARE). The products of these genes participate in numerous functions including biotransformation and redox homeostasis, lipid and iron metabolism, inflammation, proteostasis, as well as mitochondrial dynamics and energetics. Thus, it is possible that a single pharmacological NRF2 modulator might mitigate the effect of the main hallmarks of NCDs, including oxidative, proteostatic, inflammatory and/or metabolic stress. Research on model organisms has provided tremendous knowledge of the molecular mechanisms by which NRF2 affects NCDs pathogenesis. This review is a comprehensive summary of the most commonly used model organisms of NCDs in which NRF2 has been genetically or pharmacologically modulated, paving the way for drug development to combat NCDs. We discuss the validity and use of these models and identify future challenges., Research in the authors' laboratories is funded as follows: AIR and AC by the Spanish Ministry of Science, Innovation and Universities (PID2019-110061RB-I00, PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230). MGL is funded by Spanish Ministry of Science, Innovation and Universities (PID2021-125986OB-I00, PDC2022-133809-I00) and Community of Madrid Ref. P2022/BMD-7230-CAM-22. PR is funded by Spanish Ministry of Science, Innovation and Universities (PID2023-150994OB-I00), The Autonomous Community of Madrid (P2022/BMD-7227) and CIBERDEM/ISCIII (CB07/08/0033). JJV is holder of a FPU contract of Spanish Ministry of Science, Innovation and Universities (FPU20/03326). ILB is funded by the Spanish Ministry of Science, Innovation and Universities (PID2022-137065OB-100, PCD2022-133774-100) and CIBERNED/ISCIII (CB06/05/0089). MCS, ST and ASF are funded by Fundação para a Ciência e a Tecnologia through R&D unit iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020) and LS4FUTURE Associated Laboratory (LA/P/0087/2020). ASF is holder of a post-doctoral contract from “La Caixa Foundation” (NASCENT HR22-00569). IM received research core funding by Slovenian Research Agency (P3-0019). AG received research funding from the National Science Centre grant OPUS (2021/43/B/NZ4/02130). ARC is supported by the donor Henrique Meirelles who chose to support the MATRIHEALTH Project (CC1036), Fundação para a Ciência e a Tecnologia Project (https://doi.org/10.54499/PTDC/BTM-ORG/1383/2020) and Unit Funding (https://doi.org/10.54499/UIDB/00329/2020). IPT acknowledges funding from NKUA SARG (C.S. 19067). SC is funded by the ISCIII (PI23/01846). LVM is a grant holder of a contract КП-06-КОСТ/4 of the Bulgarian National Science Fund under BG-175467353-2023-03 programme. LVM and MIG have received funding from the European Union's Horizon 2020 research and innovation programme, project PlantaSYST (SGA No 739582 under FPA No. 664620) and by the European Regional Development Fund through the Bulgarian “Science and Education for Smart Growth” Operational Programme (BG05M2OP001-1.003-001-C01) and Programme Research Innovation and Digitalisation for Smart Transformation. OK is funded by the European Union Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. ADK is funded by the Medical Research Council UK (MR/W023806/1), the Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1), Tenovus Scotland (T22-08), and the Cunnigham Trust. This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mouse and human striatal projection neurons compared - somatodendritic arbor, spines and in silico analyses

  • Kozlov, Alexander K.
  • Blázquez-Llorca, Lidia
  • Benavides-Piccione, Ruth
  • Kastanauskaite, Asta
  • Rojo, Ana I.
  • Muñoz, Alberto
  • Cuadrado, Antonio
  • DeFelipe, Javier
  • Grillner, Sten
Dysfunction of the basal ganglia is implicated in a wide range of neurological and psychiatric disorders. Our understanding of the operation of the basal ganglia is largely derived on data from studies conducted on mice, which are frequently used as model organisms for various clinical conditions. The striatum, the largest compartment of the basal ganglia, consists of 90-95% striatal projection neurons (SPNs). It is therefore crucial to establish if human and mouse SPNs have distinct or similar properties, as this has implications for the relevance of mouse models for understanding the human striatum. To address this, we compared the general organization of the somato-dendritic tree of SPNs, the dimensions of the dendrites, the density and size of spines (spine surface area), and ion channel subtypes in human and mouse SPNs. Our findings reveal that human SPNs are significantly larger, but otherwise the organisation of the dendritic tree (dendrogram) with an average of approximately 5 primary dendrites, is similar in both species. Additionally in both humans and mice, over 90% of the spines are located on the terminal branches of each dendrite. Human spines are somewhat larger (4.3 versus 3.1 μm2) and the terminal dendrites have a uniform diameter in both humans and mice, although somewhat broader in the latter (1.0 versus 0.6 μm). The composition of ion channels is also largely conserved. These data have been used to simulate human SPNs building on our previous detailed simulation of mouse SPNs. We conclude that the human SPNs essentially appear as enlarged versions of the mouse SPNs. This similarity suggests that both species process information in a comparable manner, supporting the relevance of mouse models for studying the human striatum., This study was supported by the Spanish Ministry of Science and Innovation (PID2021-127924NB-I00 funded by MCIN/AEI/10.13039/501100011033) to RBP and JDF, by CIBERNED, ISCIII, CB06/05/0066 to JDF, by the Swedish Research Council (VR-M-2021-01995, VR-M-2024-01995, VR-M-2020-01652), EU/Horizon 2020 no. 945539 (HBP SGA3) and no. 101147319 (EBRAINS 2.0 Project) to SG and AK, the European Union’s Research and Innovation Program Horizon Europe under grant agreement no. 101137289 (the Virtual Brain Twin Project), the Swedish e-Science Research Centre (SeRC), Science for Life Laboratory and KTH Digital Futures to AK, by the Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy

  • García-Yagüe, Ángel Juan
  • Cañizares-Moscato, Lucía
  • Encinar, José Antonio
  • Cazalla, Eduardo
  • Fernández-Ginés, Raquel
  • Escoll, Maribel
  • Rojo, Ana I.
  • Cuadrado, Antonio
[Background] Non-communicable chronic diseases are characterized by low-grade inflammation and oxidative stress. Extensive research has identified the transcription factor NRF2 as a potential therapeutic target. Current NRF2 activators, designed to inhibit its repressor KEAP1, often exhibit undesirable side effects. As an alternative approach, we previously developed PHAR, a protein–protein interaction inhibitor of β-TrCP1/NRF2, which promotes NRF2 activation. Using the same in silico screening platform, we have now identified a novel compound, P10. This small molecule selectively interferes with the β-TrCP1/NRF2 interaction, leading to NRF2 stabilization and transcriptional activation of its target genes in a β-TrCP1-dependent manner, demonstrating promising effects in a liver model of acute inflammation., [Methods] After an in silico screening of ∼1 million compounds, including molecular docking analysis, ADMET evaluation, and molecular dynamics simulations, we identified and characterized a novel small molecule, P10, which inhibits β-TrCP1/NRF2 interaction. The compound was validated using luciferase reporter assays, co-immunoprecipitation, and ubiquitination experiments. The specificity of P10 was assessed by comparing NRF2 signatures in wild-type and Nrf2-null cells. The impact of NRF2 activation induced by P10 was investigated by evaluating its antioxidant and anti-inflammatory responses against tert-butyl hydroperoxide and lipopolysaccharide, respectively. Finally, wild-type and Nrf2-null mice were administered P10 intraperitoneally at a dose of 20 mg/kg daily for five consecutive days. Four hours before sacrifice, all animals received a lipopolysaccharide (LPS) injection at 10 mg/kg., [Results] P10 selectively disrupts the interaction between β-TrCP1 and NRF2, thereby inhibiting β-TrCP1-mediated ubiquitination of NRF2 and leading to the upregulation of NRF2 target genes. Additionally, P10 mitigates oxidative stress induced by tert-butyl hydroperoxide and reduces pro-inflammatory markers in an NRF2-dependent manner in macrophages treated with lipopolysaccharide. In a preclinical model of liver inflammation, P10 specifically targets the liver, significantly attenuating lipopolysaccharide-induced inflammation through the activation of NRF2. This is demonstrated by decreased expression of inflammatory cytokine genes and a reduction in F4/80-stained liver macrophages. Notably, this anti-inflammatory effect is absent in Nrf2-knockout mice, confirming its NRF2-dependent mechanism of action., [Conclusions] P10 emerges as a promising NRF2 activator by selectively disrupting the β-TrCP1/NRF2 interaction, highlighting its potential as a therapeutic agent for diseases presenting acute liver inflammation., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PDC2021-121421-I00, PDC2022-1337665-I00, PID2022-141786OB-I00, and PID2019-110061RB-I00). The Autonomous Community of Madrid (grants S2017BMD-3827 and P2022_BMD-7230). EC is the holder of an FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 activation by 6-MSITC increases the generation of neuroprotective, soluble α amyloid precursor protein by inducing the metalloprotease gene ADAM17

  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • Álvarez-Garrote, Sofía
  • Escoll, Maribel
  • Cuadrado, Antonio
  • Rojo, Ana I.
Better knowledge of the molecular actors governing sequential amyloid precursor protein (APP) proteolysis is crucial to endorse novel therapies aimed to delay Alzheimer's disease (AD) progression. ADAM17 (A Disintegrin and Metalloproteinase 17) is a type-I transmembrane protease involved in the non-amyloidogenic processing of APP that contributes to the maintenance of synaptic functions. In this work, we analyzed the 5′-flanking region and first intron of ADAM17 gene employing an in silico analysis. This strategy evidenced two regions which concentrate the binding sites of diverse transcription factor-families, including members of the b-ZIP small MAF, NRF2 and BACH1 proteins. Then, we found that the natural isothiocyanate 6-MSITC (6 methylsulfinyl hexyl isothiocyanate) increased both mRNA and protein levels of ADAM17 in an NRF2-dependent manner. In line, SH-SY5Y neurons released higher levels of the soluble APPα peptide as a result of ADAM17 activation. Overall, our study identifies inducible expression of ADAM17, and consequently protease activity, by NRF2., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00), CIBER -Consorcio Centro de Investigación Biomédica en Red-CB06/05/0010, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and The Autonomous Community of Madrid (grant P2022/BMD-7230). DCS is a holder of an FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Transcription factor NRF2: New therapeutic approach to modify Parkinson's disease progression

  • Rojo, Ana I.
  • Esteras, Noemí
  • Cuadrado, Antonio
  • Lastres Becker, Isabel
The lack of neuroprotective therapies for Parkinson's disease (PD) is a critical issue with significant societal and scientific relevance. The medications available, such as levodopa and dopamine agonists, focus solely on managing symptoms by temporarily replenishing dopamine or mimicking its effects. While these treatments provide relief, they do not address the root cause of the disease, allowing neurodegeneration to continue unchecked. This is why it is necessary to find new therapeutic targets that slow down the progression of the neurodegenerative process. The search for a single target capable of modulating oxidative stress, neuroinflammation, and the alteration of proteostasis associated with PD has focused on the transcription factor NRF2. Genetic variations in the NRF2 encoding NFE2L2 gene promoter that may influence disease risk and onset age have been associated with disease risk or prevention. This basic leucine-zipper protein orchestrates the expression of a battery of cytoprotective genes, all of which share a specific enhancer known as the antioxidant response element (ARE). These genes are pivotal in a variety of cellular processes, including detoxification reactions across phases I, II, and III, metabolism of glutathione and the peroxiredoxin/thioredoxin system, NADPH generation, neuroinflammation, iron management/ferroptosis, and proteostasis. Given NRF2's ability to modulate several PD's key features, various pharmacological approaches have been explored. This chapter examines the role of NRF2 in PD pathogenesis and discusses promising compounds validated in mouse models that warrant clinical trial, This work was supported by MINECO (Grants PID2022-137065OB-I00 to I.L.-B.; PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00 to AIR and AC; PID2022-137011OA-I00/AEI/10.13039/501100011033/FEDER, EU to NE), ISCiii CIBERNED (CB06/05/0089 to IL-B and NE; CB06/05/0010 to AC and AIR) and the Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC. NE is funded by a Ramón y Cajal Fellowship (RYC2021-034267-I) from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033., Peer reviewed